Cagrilintide: The Long-Acting Amylin Analogue Explained
By Peptura Research Team/22 May 2026/7 min read
What Cagrilintide Is
Cagrilintide is a long-acting synthetic analogue of human amylin from Novo Nordisk, developed as both a research compound and a clinical candidate in appetite regulation and metabolic disease. It was engineered to get around the core weakness of native amylin and earlier analogues such as pramlintide: a serum half-life so short it demands multiple daily injections to sustain any meaningful exposure. Kruse and colleagues reported its development in the Journal of Medicinal Chemistry in 2021, describing a stable lipidated amylin analogue chosen for once-weekly subcutaneous dosing.
UK researchers can source Cagrilintide from Peptura as research-grade lyophilised powder, with third-party HPLC documentation published on the product page.
Amylin and Its Receptors
Amylin, also called islet amyloid polypeptide (IAPP), is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells at mealtimes. It signals through a heterodimeric receptor system: the calcitonin receptor paired with one of three receptor activity-modifying proteins, giving the AMY1, AMY2, and AMY3 subtypes. Activating them slows gastric emptying, suppresses post-meal glucagon secretion, and engages central satiety pathways via the area postrema in the brainstem.
Native human amylin has a strong tendency to aggregate into amyloid fibrils, which makes it an awkward research tool. Cagrilintide was designed with sequence changes and lipidation to resist that aggregation while keeping receptor-binding activity, yielding a peptide fit for once-weekly subcutaneous use in research and clinical models.
Mechanism of Action
Cagrilintide acts as a pan-amylin receptor agonist, binding AMY1, AMY2, and AMY3 alongside the calcitonin receptor. Activation produces three effects that matter to metabolic research. Slowed gastric emptying stretches out post-meal nutrient absorption and prolongs satiety signalling. Suppressed post-meal glucagon secretion trims hepatic glucose output. And central activation of brainstem receptors in the area postrema shapes food intake through pathways distinct from those the GLP-1 agonists use.
That profile makes cagrilintide a natural complement to incretin-based research peptides. Where GLP-1 agonists work mainly on hypothalamic appetite circuits, cagrilintide engages brainstem satiety pathways, and the two can produce additive effects when studied together.
CagriSema: Paired With Semaglutide
Cagrilintide is often studied alongside semaglutide, a single-receptor GLP-1 agonist, under the development name CagriSema. The logic is mechanistic: amylin and GLP-1 receptor agonism recruit distinct neural circuits and add up on energy intake in research models. D'Ascanio and colleagues reviewed the rationale in Cardiology in Review in 2023, noting that the separate but related mechanisms of an amylin analogue and a GLP-1 agonist appear to deliver additive appetite reduction.
For the wider incretin and metabolic peptide picture, the Retatrutide triple receptor agonist research guide covers an alternative multi-receptor route using a single molecule rather than a combination, while the Retatrutide vs Semaglutide research comparison frames single versus multi-receptor research peptides.
The Phase 2 Evidence
Lau and colleagues published Phase 2 data on cagrilintide monotherapy in The Lancet in 2021. The trial enrolled 706 participants across ten countries and reported dose-dependent weight reductions over 26 weeks, with the highest dose, 4.5 mg once-weekly, producing a mean weight reduction of 10.8 percent against 3.0 percent for placebo. An active comparator arm with liraglutide 3.0 mg was also included, and the top cagrilintide dose produced numerically greater weight loss than it.
Frias and colleagues then reported Phase 2 data on the CagriSema combination in The Lancet in 2023. Over 32 weeks in participants with type 2 diabetes, CagriSema produced mean weight loss of 15.6 percent versus 5.1 percent for semaglutide alone and 8.1 percent for cagrilintide alone, in line with the additive-mechanism hypothesis. Phase 3 trials under the REDEFINE programme are ongoing.
Laboratory Handling
Cagrilintide comes as a lyophilised powder. Store at -20°C before reconstitution to protect integrity. Reconstitute with bacteriostatic water by running the diluent slowly down the inner wall of the vial and swirling gently. Never shake, since the shear stress and air bubbles it creates can degrade peptide bonds. Keep the reconstituted solution at 2-8°C and use within four weeks, avoiding repeated freeze-thaw cycles.
Sourcing in the UK
Peptura supplies research-grade Cagrilintide as lyophilised powder from GMP-certified manufacturers, with full third-party HPLC documentation published on the product page. Same-day UK dispatch on orders placed before 2pm GMT, free Royal Mail Tracked shipping over £45. Strictly for in-vitro laboratory research only, not for human consumption.
Related Products
Disclaimer: This article is for research and educational purposes only. All information provided is not intended as medical advice. Peptura products are not for human consumption and are sold strictly for laboratory research use only.